{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:25:31Z","timestamp":1788809131827,"version":"build-2803163510"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH), thereby lowering testosterone to castrate levels. This is associated with adverse events (AEs), including cardiovascular (CV) disorders, bone fractures, metabolic dysfunction, and impaired cognitive function. This literature review discusses these AEs, with a focus on CV and bone-related events. A hypothesis-generating meta-analysis of six clinical trials showed a potentially increased risk for CV disorders with GnRH agonists versus the GnRH antagonist degarelix. While no study has directly compared GnRH agonists versus antagonists with a primary CV outcome, one hypothesis for this observation is that GnRH agonists lead to initial surges in FSH that may negatively impact CV health, whereas antagonists do not. GnRH agonists are associated with metabolic and cognitive AEs and while data are lacking for GnRH antagonists, no differences in risk are predicted. Other common AEs with ADT include injection site reactions, which are much more common with degarelix than with GnRH agonists, which may reflect differing administration and injection techniques. Future studies are needed to further evaluate and compare the safety profiles of GnRH agonists and antagonists, especially in patients with pre-existing CV disease and other co-morbidities. Physicians should carefully evaluate benefits and risks when prescribing ADT and ensure that side effects are well managed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aja.aja_22_20","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T14:49:29Z","timestamp":1594306169000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["Androgen deprivation therapy and side effects"],"prefix":"10.4103","volume":"23","author":[{"given":"Stephen J","family":"Freedland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Anders","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240829","first-page":"S3","article-title":"Hormonal therapy in prostate cancer: historical approaches","volume":"6","author":"Crawford","year":"2004","journal-title":"Rev Urol"},{"key":"R2-2-20240829","first-page":"5","article-title":"The role of the FSH system in the development and progression of prostate cancer","volume":"10","author":"Crawford","year":"2014","journal-title":"Am J Hematol Oncol"},{"key":"R3-2-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12610-015-0023-2","article-title":"Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist","volume":"25","author":"Miyazawa","year":"2015","journal-title":"Basic Clin Androl"},{"key":"R4-2-20240829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/pcan.2017.10","article-title":"Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis","volume":"20","author":"Nead","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R5-2-20240829","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2016.35","article-title":"A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients","volume":"19","author":"Jin","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R6-2-20240829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2015.50","article-title":"Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer","volume":"19","author":"Mitsuzuka","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R7-2-20240829","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.urology.2007.12.070","article-title":"Testosterone surge: rationale for gonadotropin-releasing hormone blockers?","volume":"71","author":"van Poppel","year":"2008","journal-title":"Urology"},{"key":"R8-2-20240829","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1756287215621471","article-title":"Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials","volume":"8","author":"Iversen","year":"2016","journal-title":"Ther Adv Urol"},{"key":"R9-2-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/pcan.2012.25","article-title":"New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists","volume":"16","author":"Shore","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R10-2-20240829","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(01)61831-7","article-title":"Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)","volume":"161","author":"Ben-Josef","year":"1999","journal-title":"J Urol"},{"key":"R11-2-20240829","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1464-410X.2011.10708.x","article-title":"New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist","volume":"110","author":"Garnick","year":"2012","journal-title":"BJU Int"},{"key":"R12-2-20240829","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"R13-2-20240829","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"R14-2-20240829","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"R15-2-20240829","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.2011.1791","article-title":"Androgen deprivation therapy and competing risks","volume":"306","author":"Kelly","year":"2011","journal-title":"JAMA"},{"key":"R16-2-20240829","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"R17-2-20240829","doi-asserted-by":"crossref","first-page":"99","DOI":"10.21037\/atm.2016.01.23","article-title":"Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer","volume":"4","author":"Karantanos","year":"2016","journal-title":"Ann Transl Med"},{"key":"R18-2-20240829","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R19-2-20240829","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/cncr.28594","article-title":"Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer","volume":"120","author":"Roach","year":"2014","journal-title":"Cancer"},{"key":"R20-2-20240829","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","article-title":"The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study","volume":"114","author":"Gandaglia","year":"2014","journal-title":"BJU Int"},{"key":"R21-2-20240829","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"key":"R22-2-20240829","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"R23-2-20240829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R24-2-20240829","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/jco.2015.33.7_suppl.151","article-title":"Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: exploratory analysis of a randomized controlled trial","volume":"33","author":"Higano","year":"2015","journal-title":"J Clin Oncol"},{"key":"R25-2-20240829","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"R26-2-20240829","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11934-017-0688-5","article-title":"Approach to androgen deprivation in the prostate cancer patient with pre-existing cardiovascular disease","volume":"18","author":"Greiman","year":"2017","journal-title":"Curr Urol Rep"},{"key":"R27-2-20240829","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/14656566.2017.1328056","article-title":"Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer","volume":"18","author":"Clinton","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R28-2-20240829","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4111\/kju.2015.56.1.12","article-title":"Metabolic effects of androgen deprivation therapy","volume":"56","author":"Choi","year":"2015","journal-title":"Korean J Urol"},{"key":"R29-2-20240829","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond"},{"key":"R30-2-20240829","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00345-016-1818-2","article-title":"The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK","volume":"34","author":"Rosario","year":"2016","journal-title":"World J Urol"},{"key":"R31-2-20240829","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","article-title":"The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy","volume":"86","author":"Conteduca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R32-2-20240829","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"key":"R33-2-20240829","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"R34-2-20240829","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/acel.12331","article-title":"FSH regulates fat accumulation and redistribution in aging through the Galphai\/Ca(2+)\/CREB pathway","volume":"14","author":"Liu","year":"2015","journal-title":"Aging Cell"},{"key":"R35-2-20240829","first-page":"599","article-title":"Gonadotropin-releasing hormone antagonists in prostate cancer","volume":"32","author":"Kittai","year":"2018","journal-title":"Oncology (Williston Park"},{"key":"R36-2-20240829","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12885-016-2221-5","article-title":"Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review","volume":"16","author":"Meng","year":"2016","journal-title":"BMC Cancer"},{"key":"R37-2-20240829","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41391-018-0059-4","article-title":"Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis","volume":"21","author":"Guo","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R38-2-20240829","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1210\/jc.2007-0454","article-title":"Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism","volume":"92","author":"Yialamas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-2-20240829","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R40-2-20240829","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2004-1158","article-title":"Endogenous sex hormones and metabolic syndrome in aging men","volume":"90","author":"Muller","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-2-20240829","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"R42-2-20240829","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLoS One"},{"key":"R43-2-20240829","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-2-20240829","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung","year":"2014","journal-title":"Int J Mol Sci"},{"key":"R45-2-20240829","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"R46-2-20240829","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2007.08.012","article-title":"Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer","volume":"70","author":"Lage","year":"2007","journal-title":"Urology"},{"key":"R47-2-20240829","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJM199604113341504","article-title":"Hyperinsulinemia as an independent risk factor for ischemic heart disease","volume":"334","author":"Despres","year":"1996","journal-title":"N Engl J Med"},{"key":"R48-2-20240829","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/jdi.12472","article-title":"Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis","volume":"7","author":"Wang","year":"2016","journal-title":"J Diabetes Investig"},{"key":"R49-2-20240829","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-2-20240829","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.1994.tb02475.x","article-title":"Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men","volume":"40","author":"Behre","year":"1994","journal-title":"Clin Endocrinol (Oxf"},{"key":"R51-2-20240829","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf"},{"key":"R52-2-20240829","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"R53-2-20240829","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"R54-2-20240829","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cncr.21381","article-title":"Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"R55-2-20240829","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.10967","article-title":"Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"R56-2-20240829","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MED.0b013e3283398ee2","article-title":"Androgens and obesity","volume":"17","author":"Allan","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R57-2-20240829","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"R58-2-20240829","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R59-2-20240829","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"R60-2-20240829","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States","volume":"21","author":"Beebe-Dimmer","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R61-2-20240829","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00774-014-0629-z","article-title":"Sex hormone levels as determinants of bone mineral density and osteoporosis in Vietnamese women and men","volume":"33","author":"Nguyen","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"R62-2-20240829","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.2047-2927.2013.00093.x","article-title":"Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines","volume":"1","author":"Cheung","year":"2013","journal-title":"Andrology"},{"key":"R63-2-20240829","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1464-410X.2009.08981.x","article-title":"Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study","volume":"106","author":"Schroder","year":"2010","journal-title":"BJU Int"},{"key":"R64-2-20240829","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cyto.2010.11.011","article-title":"Follicle-stimulating hormone promotes RANK expression on human monocytes","volume":"53","author":"Cannon","year":"2011","journal-title":"Cytokine"},{"key":"R65-2-20240829","doi-asserted-by":"crossref","first-page":"R790","DOI":"10.1152\/ajpregu.00728.2009","article-title":"Follicle-stimulating hormone, interleukin-1, and bone density in adult women","volume":"298","author":"Cannon","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R66-2-20240829","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.juro.2011.04.083","article-title":"A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer","volume":"186","author":"Crawford","year":"2011","journal-title":"J Urol"},{"key":"R67-2-20240829","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.urology.2014.01.013","article-title":"Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix","volume":"83","author":"Crawford","year":"2014","journal-title":"Urology"},{"key":"R68-2-20240829","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12894-015-0116-4","article-title":"Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for uro-oncological quality assurance) Firmagon\u00ae registry","volume":"15","author":"Geiges","year":"2015","journal-title":"BMC Urol"},{"key":"R69-2-20240829","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","article-title":"Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide","volume":"25","author":"Mason","year":"2013","journal-title":"Clin Oncol (R Coll Radiol"},{"key":"R70-2-20240829","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","article-title":"Androgen deprivation therapy and future Alzheimer's disease risk","volume":"34","author":"Nead","year":"2016","journal-title":"J Clin Oncol"},{"key":"R71-2-20240829","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/pon.3932","article-title":"Androgen deprivation therapy's impact on the mood of prostate cancer patients as perceived by patients and the partners of patients","volume":"25","author":"Van Dam","year":"2016","journal-title":"Psychooncology"},{"key":"R72-2-20240829","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"R73-2-20240829","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"key":"R74-2-20240829","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/1008-682X.125410","article-title":"Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research","volume":"16","author":"Parikh","year":"2014","journal-title":"Asian J Androl"},{"key":"R75-2-20240829","doi-asserted-by":"crossref","first-page":"e000040","DOI":"10.1136\/esmoopen-2016-000040","article-title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","volume":"1","author":"Liede","year":"2016","journal-title":"ESMO Open"},{"key":"R76-2-20240829","first-page":"28","article-title":"Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice","volume":"21","author":"Dason","year":"2014","journal-title":"Can J Urol"},{"key":"R77-2-20240829","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1756287215617872","article-title":"Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?","volume":"8","author":"Zareba","year":"2016","journal-title":"Ther Adv Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_22_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:22Z","timestamp":1786735702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_22_20"}},"subtitle":["are GnRH antagonists safer?"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/aja.aja_22_20","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}